If you've watched The Handmaid’s Tale, you'll know that the show has no shortage of disturbing characters - from Commander ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

The Handmaid’s Tale has introduced its fair share of unsettling figures over the years, but none have shaken things up quite ...

The virologist, awarded for his part in the discovery of the hepatitis C virus, has helped save the lives of millions of ...

Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,708.95 today based on a price of $111.70 for GILD at the time of writing.

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Union momentum grows in Ireland’s €100bn pharma sector as Trump’s tariff threats and weak labour laws fuel worker unrest ...

A new twice-yearly antiviral injection that can prevent HIV is likely to be approved soon in Australia. Making it affordable ...

But after the rather open-ended Handmaid’s Tale  series finale in May, we have questions that still need answers. The Testaments follows three protagonists: Aunt Lydia (Ann Dowd), Agnes/Hannah (Chase ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

The July 24 event aims to inspire accessible and impactful philanthropy by breaking down barriers to meaningful change.